Disease and treatment burden of psoriasis: Examining the impact of biologics

Journal of Drugs in Dermatology

Volumn 10, Issue 2, 2011, Pages 189-196

  Raval, Kalindi ^a   Lofland, Jennifer H ^b   Waters, Heidi C ^b   Piech, Catherine Tak ^b  

^a XCENDA   (United States)

^b CENTOCOR INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PLACEBO; BIOLOGICAL PRODUCT;

ABSENTEEISM; ARTICLE; BIOLOGICAL THERAPY; CONSULTATION; CORTICOSTEROID THERAPY; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; MEDLINE; PATIENT COMPLIANCE; PATIENT PREFERENCE; PATIENT SATISFACTION; PHOTOTHERAPY; PRACTICE GUIDELINE; PRODUCTIVITY; PSORIASIS; PSORIASIS VULGARIS; PUVA; QUALITY OF LIFE; SKIN INFLAMMATION; SYSTEMATIC REVIEW; ULTRAVIOLET B RADIATION; VISUAL ANALOG SCALE; CHRONIC DISEASE; CLINICAL TRIAL (TOPIC); DRUG EFFECT; HEALTH CARE PLANNING; REVIEW; UTILIZATION REVIEW;

BIOLOGICAL PRODUCTS; BIOLOGICAL THERAPY; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; EFFICIENCY; HEALTH RESOURCES; HUMANS; PATIENT COMPLIANCE; PATIENT SATISFACTION; PSORIASIS; PUVA THERAPY;

EID: 80052071679     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Schon MP, Boehncke WH. Psoriasis. N Engl J Med. 2005;352:1899-1912. (Pubitemid 40627816)
2. Horn EJ, Fox KM, Patel V, et al. Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey. J Am Acad Dermatol. 2007;57:957-962. (Pubitemid 350087339)
3. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin. 1996;14:485-496. (Pubitemid 26249398)
4. Stern RS, Nijsten T, Feldman SR, et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9:136-139. (Pubitemid 38457271)
5. Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: Results of a 1998 National Psoriasis Foundation patient- membership survey. Arch Dermatol. 2001;137:280-284. (Pubitemid 32240779)
6. Javitz HS, Ward MM, Farber E, et al. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol. 2002;46:850-860.
7. United States Department of Labor Bureau of Labor Statistics. Available at http://www.bls.gov/bls/inflation.htm. Accessed March 2009.
8. Berger K, Ehlken B, Kugland B, et al. Cost-of-illness in patients with moderate and severe chronic psoriasis vulgaris in Germany. J Dtsch Dermatol Ges. 2005;3:511-518. (Pubitemid 40942633)
9. Jenner N, Campbell J, Plunkett A, et al. Cost of psoriasis: A study on the morbidity and financial effects of having psoriasis in Australia. Australas J Dermatol. 2002;43:255-261. (Pubitemid 35365414)
10. Finlay AY, Ortonne JP. Patient satisfaction with psoriasis therapies: An update and introduction to biologic therapy. J Cutan Med Surg. 2004;8:310-320. (Pubitemid 41542421)
11. Richards HL, Fortune DG, O'Sullivan TM, et al. Patients with psoriasis and their compliance with medication. J Am Acad Dermatol. 1999;41:581-583. (Pubitemid 29480408)
12. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826-850. (Pubitemid 351509656)
13. Humira: Package insert. Abbott Park, IL: Abbott Laboratories; 2009.
14. Amevive: Package insert. Deerfield, IL: Astellas Pharma US, Inc.; 2006.
15. Enbrel: Package insert. Thousand Oaks, CA.: Immunex Corp.; 2008.
16. Remicade: Package insert. Malvern, PA: Centocor, Inc.; 2008.
17. Nijsten T, Margolis DJ, Feldman SR, et al. Traditional systemic treatments have not fully met the needs of psoriasis patients: Results from a national survey. J Am Acad Dermatol. 2005;52:434-444.
18. Uttjek M, Dufaker M, Nygren L, et al. Determinants of quality of life in a psoriasis population in northern Sweden. Acta Derm Venereol. 2004;84:37-43. (Pubitemid 38168361)
19. Ersser SJ, Surridge H, Wiles A. What criteria do patients use when judging the effectiveness of psoriasis management? J Eval Clin Pract. 2002;8:367-376. (Pubitemid 35402833)
20. Fouere S, Adjadj L, Pawin H. How patients experience psoriasis: Results from a European survey. J Eur Acad Dermatol Venereol. 2005;19 Suppl 3:2-6. (Pubitemid 41726918)
21. Jones-Caballero M, Unaeze J, Penas PF, et al. Use of biological agents in patients with moderate to severe psoriasis: A cohort-based perspective. Arch Dermatol. 2007;143:846-850. (Pubitemid 47076481)
22. Wu Y, Mills D, Barrett J, et al. Poor patient satisfaction and medication adherence among patients with psoriasis: Results from a large national survey. Psoriasis Forum. 2007;13:22-26.
23. Carroll CL, Feldman SR, Camacho FT, et al. Better medication adherence results in greater improvement in severity of psoriasis. Br J Dermatol. 2004;151:895-897. (Pubitemid 39482127)
24. Storm A, Andersen SE, Benfeldt E, et al. One in 3 prescriptions are never redeemed: primary nonadherence in an outpatient clinic. J Am Acad Dermatol. 2008;59:27-33.
25. Zaghloul SS, Goodfield MJ. Objective assessment of compliance with psoriasis treatment. Arch Dermatol. 2004;140:408-414. (Pubitemid 38469243)
26. Kulkarni AS, Balkrishnan R, Camacho FT, et al. Medication and health care service utilization related to depressive symptoms in older adults with psoriasis. J Drugs Dermatol. 2004;3:661-666.
27. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24:67-74. (Pubitemid 16125389)
28. Bhosle MJ, Feldman SR, Camacho FT, et al. Medication adherence and health care costs associated with biologics in Medicaid-enrolled patients with psoriasis. J Dermatolog Treat. 2006;17:294-301. (Pubitemid 44595018)
29. Crown WH, Bresnahan BW, Orsini LS, et al. The burden of illness associated with psoriasis: Cost of treatment with systemic therapy and phototherapy in the US. Curr Med Res Opin. 2004;20:1929-1936. (Pubitemid 40179632)
30. Gelfand JM, Kimball AB, Mostow EN, et al. Patient-reported outcomes and health-care resource utilization in patients with psoriasis treated with etanercept: Continuous versus interrupted treatment. Value Health. 2008;11:400-407. (Pubitemid 351712967)
31. Schmitt JM, Ford DE. Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis. Dermatology. 2006;213:102-110. (Pubitemid 44215193)
32. Reich K, Nestle FO, Wu Y, et al. Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis. Eur J Dermatol. 2007;17:381-386. (Pubitemid 47425903)
33. Carr AJ, Thompson PW, Cooper C. Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: A cross-sectional survey. Osteoporos Int. 2006;17:1638-1644. (Pubitemid 44477624)
34. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371:1665-1674. (Pubitemid 351671883)
35. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371:1675-1684. (Pubitemid 351671884)
36. Reich K, Schenkel B, Zhao N, et al. Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: Results from PHOENIX 2. J Dermatolog Treat. E-oub Oct 31 2010.
37. Lofland JH, Pizzi L, Frick KD. A review of health-related workplace productivity loss instruments. Pharmacoeconomics. 2004;22:165-184. (Pubitemid 38333649)
38. Burton WN, Conti DJ. The real measure of productivity. Bus Health. 1999;17:34-36.
39. Lofland JH, Nash DB. Oral serotonin receptor agonists: A review of their cost effectiveness in migraine. Pharmacoeconomics. 2005;23:259-274. (Pubitemid 40663632)
40. Kimball AB, Jackson JM, Sobell JM, et al. Reductions in healthcare resource utilization in psoriatic arthritis patients receiving etanercept therapy: Results from the educate trial. J Drugs Dermatol. 2007;6:299-306.
41. Atkinson MJ, Sinha A, Hass SL, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004;2:12.